vida: extract claims from 2026-04-24-glp1-oud-rct-protocol-nct06548490-penn-state

- Source: inbox/queue/2026-04-24-glp1-oud-rct-protocol-nct06548490-penn-state.md
- Domain: health
- Claims: 0, Entities: 1
- Enrichments: 0
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md

@@ -10,17 +10,10 @@ agent: vida
 sourced_from: health/2026-04-23-glp1-substance-use-disorder-33-trials.md
 scope: causal
 sourcer: PubMed/ClinicalTrials.gov systematic review
-challenges:
-- medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm
-related:
-- glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation
-- medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm
-supports:
-- The behavioral-biological health determinant dichotomy is false for obesity because what appears as behavioral overconsumption is dopamine reward dysregulation continuously activated by the food environment
-- Hedonic eating is mediated by dopamine reward circuits that adapt to GLP-1 suppression explaining both why GLP-1s work and why they require continuous delivery
-reweave_edges:
-- The behavioral-biological health determinant dichotomy is false for obesity because what appears as behavioral overconsumption is dopamine reward dysregulation continuously activated by the food environment|supports|2026-04-24
-- Hedonic eating is mediated by dopamine reward circuits that adapt to GLP-1 suppression explaining both why GLP-1s work and why they require continuous delivery|supports|2026-04-24
+challenges: ["medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm"]
+related: ["glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement"]
+supports: ["The behavioral-biological health determinant dichotomy is false for obesity because what appears as behavioral overconsumption is dopamine reward dysregulation continuously activated by the food environment", "Hedonic eating is mediated by dopamine reward circuits that adapt to GLP-1 suppression explaining both why GLP-1s work and why they require continuous delivery"]
+reweave_edges: ["The behavioral-biological health determinant dichotomy is false for obesity because what appears as behavioral overconsumption is dopamine reward dysregulation continuously activated by the food environment|supports|2026-04-24", "Hedonic eating is mediated by dopamine reward circuits that adapt to GLP-1 suppression explaining both why GLP-1s work and why they require continuous delivery|supports|2026-04-24"]
 ---
 
 # GLP-1 receptor agonists may address multiple substance use disorders through shared mesolimbic dopamine circuit modulation with 33 clinical trials underway across alcohol opioid nicotine and cocaine use
@@ -32,4 +25,10 @@ A systematic review of ClinicalTrials.gov identified 33 registered trials examin
 
 **Source:** Zhu et al., Science 2025, Vol. 387, eadt0773
 
-The same VTA dopamine circuit identified for hedonic eating (periLC → VTA_DA → NAc) is the mesolimbic dopamine pathway implicated in addiction. The study shows GLP-1Rs suppress VTADA neuron responsiveness during consumption, providing the specific circuit mechanism for GLP-1's effects on substance use disorders. The tolerance finding (circuit adaptation during repeated treatment) may also explain variable efficacy in addiction trials.
+The same VTA dopamine circuit identified for hedonic eating (periLC → VTA_DA → NAc) is the mesolimbic dopamine pathway implicated in addiction. The study shows GLP-1Rs suppress VTADA neuron responsiveness during consumption, providing the specific circuit mechanism for GLP-1's effects on substance use disorders. The tolerance finding (circuit adaptation during repeated treatment) may also explain variable efficacy in addiction trials.
+
+## Extending Evidence
+
+**Source:** Annals of Internal Medicine 2024, target trial emulation + exenatide RCT
+
+Target trial emulation (real-world data) shows semaglutide associated with significantly lower risk of medical encounters for tobacco use disorder diagnosis compared with other antidiabetes medications, with strongest effect vs. insulins. Phase 2 RCT (exenatide + NRT) showed increased smoking abstinence vs. placebo + NRT, with reduced cravings and withdrawal symptoms. However, dulaglutide + varenicline RCT showed null result, likely due to ceiling effect (adding GLP-1 to already-effective varenicline). Mechanism consistent with VTA dopamine pathway modulation. This extends the reward circuit claim to a third substance type (tobacco), though evidence is mixed compared to AUD and obesity.

entities/health/nct06548490-semaglutide-oud-phase2.md

@@ -0,0 +1,81 @@
+# NCT06548490: Semaglutide for OUD Phase 2 RCT
+
+**Type:** Clinical Trial Protocol
+**Status:** Active (ongoing, no results)
+**Phase:** 2
+**Design:** Randomized, double-blind, placebo-controlled
+**Registration:** NCT06548490
+**Principal Investigator:** Patricia S. Grigson, Penn State
+**Funding:** NIH
+**Publication:** Addiction Science & Clinical Practice, 2025
+
+## Trial Design
+
+**Population:**
+- 200 participants with treatment-refractory opioid use disorder
+- Already receiving standard MOUD (buprenorphine or methadone)
+- Outpatient setting
+- Three sites
+
+**Intervention:**
+- Semaglutide vs. placebo
+- 12-week treatment period
+- Added to existing MOUD background therapy
+
+**Primary Endpoint:**
+- Opioid abstinence (confirmed by urine drug screens + self-report)
+
+## Scientific Rationale
+
+**Preclinical Evidence:**
+- Rodent models show GLP-1 receptor agonists reduce opioid self-administration
+- Mechanism: GLP-1 receptors in ventral tegmental area modulate dopamine reward circuits
+
+**Clinical Evidence (pre-trial):**
+- Residential OUD population studies show decreased craving measures
+- Qeadan 2025 real-world data: 40% lower opioid overdose rate in GLP-1 RA users
+- No completed controlled trials in outpatient OUD as of protocol publication
+
+## Safety Considerations
+
+**Documented Concerns:**
+- Pancreatic cysts and cancer risk
+- Hypoglycemia
+- Muscle cramps
+- Cognitive slowing
+- Drug interactions with buprenorphine/methadone
+
+**Population Risk:**
+- Treatment-refractory patients represent high-difficulty population
+- Higher baseline risk for adverse outcomes
+
+## Significance
+
+**Why This Trial Matters:**
+- Only active well-powered Phase 2 RCT for GLP-1 in OUD
+- Tests whether real-world observational signal (Qeadan 2025) holds under controlled conditions
+- Specifically targets treatment-refractory population (not achieving abstinence with standard MOUD)
+- Will determine if GLP-1 reward circuit mechanism extends beyond food/alcohol to opioids
+
+**Expected Timeline:**
+- Results anticipated 2026-2027
+- Positive result would elevate GLP-1 OUD mechanism claim from "experimental" to "likely" confidence
+- Null result would suggest mechanism specificity to food/alcohol reward circuits
+
+## Timeline
+
+- **2025** — Protocol published in Addiction Science & Clinical Practice
+- **2025-2026** — Trial enrollment and treatment ongoing
+- **2026-2027** — Results expected (monitoring required)
+
+## Research Context
+
+Patricia Grigson is a leading addiction neuroscience researcher at Penn State College of Medicine. This NIH-funded trial represents the first rigorous controlled test of GLP-1 receptor agonists for opioid use disorder in an outpatient population already receiving medication-assisted treatment.
+
+## Monitoring Notes
+
+**Status:** Protocol-only publication. No results available as of April 2026.
+
+**Action Required:** Monitor for results publication Q3/Q4 2026 or early 2027. Results will directly inform whether the GLP-1 reward circuit mechanism claim can extend to opioids with "likely" confidence.
+
+**KB Impact:** When results publish, this becomes a primary source for evaluating the OUD extension of the existing claim "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation"

inbox/archive/health/2026-04-24-annals-im-semaglutide-tobacco-use-disorder-real-world.md

@@ -7,9 +7,12 @@ date: 2024
 domain: health
 secondary_domains: []
 format: peer-reviewed study
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-24
 priority: low
 tags: [glp-1, semaglutide, smoking, tobacco, nicotine, addiction, real-world-data, reward-circuit, VTA-dopamine]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content

inbox/archive/health/2026-04-24-glp1-oud-rct-protocol-nct06548490-penn-state.md

@@ -7,9 +7,12 @@ date: 2025
 domain: health
 secondary_domains: []
 format: peer-reviewed study
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-24
 priority: medium
 tags: [glp-1, semaglutide, opioid-use-disorder, OUD, addiction, clinical-trial, Phase-2, VTA-dopamine, reward-circuit, NCT06548490]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content